World J Gastroenterol. 2010 Feb 21;16(7):800-3. doi: 10.3748/wjg.v16.i7.800.
In our examination of the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD), non-obese NAFLD patients without insulin resistance presented a characteristic pattern of dietary intake. Dietary cholesterol intake was superabundant in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Namely, excess cholesterol intake appears to be one of the main factors associated with NAFLD development and liver injury. Therefore, the control of dietary cholesterol intake may lead to an improvement in NAFLD, and the NPC1L1 inhibitor ezetimibe might be a promising treatment for NAFLD. We review one pathogenic aspect of lipid metabolism dysregulation in NAFLD and survey new strategies for NAFLD treatment based on the modification of cholesterol metabolism.
在研究非酒精性脂肪性肝病（NAFLD）患者的腹部脂肪分布、饮食摄入和生化数据时，我们发现非肥胖且无胰岛素抵抗的 NAFLD 患者存在一种特征性的饮食摄入模式。与肥胖患者相比，非肥胖患者的膳食胆固醇摄入量过高，尽管总能量和碳水化合物摄入量并不超标。也就是说，过量的胆固醇摄入似乎是与 NAFLD 发展和肝损伤相关的主要因素之一。因此，控制膳食胆固醇摄入可能有助于改善 NAFLD，而 NPC1L1 抑制剂依折麦布可能是治疗 NAFLD 的一种有前途的药物。我们回顾了 NAFLD 脂质代谢失调的一个发病机制方面，并根据胆固醇代谢的改变调查了 NAFLD 治疗的新策略。
